Glu-857 Moderates K+-dependent Stimulation and SCH  28080-dependent Inhibition of the Gastric H,K-ATPase*

S. J. Rulli, M. N. Horiba, E. Skripnikova, and E. C. RabonDagger

From the Department of Physiology, Tulane University Medical Center and the Department of Veterans Affairs, New Orleans, Louisiana 70112

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The rabbit H,K-ATPase alpha - and beta -subunits were transiently expressed in HEK293 T cells. The co-expression of the H,K-ATPase alpha - and beta -subunits was essential for the functional H,K-ATPase. The K+-stimulated H,K-ATPase activity of 0.82 ± 0.2 µmol/mg/h saturated with a K0.5 (KCl) of 0.6 ± 0.1 mM, whereas the 2-methyl-8-(phenylmethoxy)imidazo[1,2a]pyridine-3-acetonitrile (SCH 28080)-inhibited ATPase of 0.62 ± 0.07 µmol/mg/h saturated with a Ki (SCH 28080) of 1.0 ± 0.3 µM. Site mutations were introduced at the N,N-dicyclohexylcarbodiimide-reactive residue, Glu-857, to evaluate the role of this residue in ATPase function. Variations in the side chain size and charge of this residue did not inhibit the specific activity of the H,K-ATPase, but reversal of the side chain charge by substitution of Lys or Arg for Glu produced a reciprocal change in the sensitivity of the H,K-ATPase to K+ and SCH 28080. The K0.5 for K+stimulated ATPase was decreased to 0.2 ± .05 and 0.2 ± .03 mM, respectively, in Lys-857 and Arg-857 site mutants, whereas the Ki for SCH 28080-dependent inhibition was increased to 6.5 ± 1.4 and 5.9 ± 1.5 µM, respectively. The H,K-ATPase kinetics were unaffected by the introduction of Ala at this site, but Leu produced a modest reciprocal effect. These data indicate that Glu-857 is not an essential residue for cation-dependent activity but that the residue influences the kinetics of both K+ and SCH 28080-mediated functions. This finding suggests a possible role of this residue in the conformational equilibrium of the H,K-ATPase.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The gastric H,K-ATPase produces the acidic environment of the gastric mucosa through an electroneutral exchange of H+ for K+ (1, 2). It is a member of a phosphoenzyme-forming ATPase family (P2)1 that includes the Ca-ATPase, the Na,K-ATPase, and the Neurospora H+ pump (3). This family of transporters and the more distantly related P1 and P3 ATPase families display important functional variations in the specificity and stoichiometry of transported ions, inhibitor sensitivities, cellular distribution, and subunit organization.

The H,K-ATPase gene family within the P2 ion pump family is composed of at least five alpha -subunit isomers and, as known to date, a single beta -subunit. The ATPase is a heterodimer composed of a Mr 114,000 catalytic subunit and a smaller, Mr 34,000 glycosylated beta -subunit (4-6). The primary structure of the gastric alpha -subunit isoform is highly conserved among various mammalian species including rat (7), rabbit (8), hog (9), and man (10), but sequence conservation deteriorates in H,K-ATPase isoforms present in the urinary bladder (11), skin (12), colon (13), and kidney (14) as well as in other P2-type pump isoforms (15, 16).

The P2 family of ion pumps consists of polytopic membrane proteins generally modeled with 8-10 membrane spanning regions. A variety of evidence has yielded a consensus for the identity of the transmembrane spanning domains M1-M4 within the N-terminal half of the ATPases (17-21) but has not conclusively defined the C-terminal transmembrane spanning domains (22-25).

Although the organization of the C-terminal membrane spanning domains remains a focus of investigation, there is general consensus that charged residues within these domains participate in cation-dependent function. Cation binding to membrane-embedded proteolytic fragments is dependent upon the integrity of the ATPase from M5 to the C terminus in both the Na,K-ATPase and the H,K-ATPase (17, 19, 26, 27). The disruption of the C-terminal sequence at the cytoplasmic-M7 interface facilitates the thermal inactivation of ATPase (28, 29), release of the putative M5-M6 hairpin to the supernatant (30), and exposure of Cys-983 (31). Amino acid substitutions within membrane spanning segments of M4, M5, M6, and M8 have identified conserved residues in the expressed Na,K-ATPase, Ca-ATPase, and H,K-ATPase that are essential for ion-dependent transport or cation-dependent catalytic activity (32-39).

Chemical modification studies utilizing carboxyl reagents such as DEAC (40) and DCCD (41-45) have investigated the role of hydrophobic carboxyl groups in several pumps within the P2 pump family. These studies show that protection from inhibition by the transported cation is a general characteristic of the inhibitor-dependent inactivation of these ATPases. Even though the mechanism of inactivation is controversial, the cation specificity and concentration dependence providing protection have frequently been interpreted as evidence for the modification of residues within the cation binding site. A microsequence has now been obtained for several reactive residues in or near transmembrane spanning domains within M5, M7, and M9 of the native H,K-ATPase (45) and Na,K-ATPase (44, 46). Mutational studies of the modified residue and analysis of the expressed Na,K-ATPase have provided evidence to confirm biochemical studies that Glu-779 (NIPE), a DEAC-reactive site, is important for cation-dependent activity (46-48) but contradicted a similar biochemical study that Glu-959 (FEET), a [14C]DCCD-reactive site (44, 47, 49), is important for Na,K-ATPase activity.

Glu-857 (LVNE), a residue at the fourth putative cytosolic-seventh transmembrane spanning region interface (C4-M7) of the gastric H,K-ATPase has been identified as a K+-protected, [14C]DCCD-reactive site (45). To clarify whether DCCD-dependent inhibition is the result of its modification of an essential residue within the cation binding site of the H,K-ATPase or whether inhibition may result from a secondary effect, such as cross-linkage or cation-dependent protection of a DCCD-reactive site at an alternative locus, a series of site mutants were prepared at this position varying the size, charge, and hydrophobicity of the side chain residue. The site mutants were transiently expressed in HEK293 T cells, and the expressed H,K-ATPase was analyzed to determine the effect of the modifications on the steady-state kinetic constants describing K+-stimulated activation or SCH 28080-dependent inhibition of the ATPase.

The results of this investigation demonstrate that Glu-857 is not essential for K+-dependent ATPase activity but do suggest that the C4-M7 domain is an important region involved in the conformational sensitivity of the molecule.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Plasmid Constructs-- Plasmids containing the alpha -subunit (GenBank accession number X64694) and beta -subunit (GenBank accession number M35544) of the rabbit (Oryctolagus cuniculus) gastric H,K-ATPase in the vector pcDNA3 (Invitrogen) were a kind gift of Dr. George Sachs (Wadsworth Veterans Affairs Medical Center, UCLA). Bidirectional sequence analysis of the 5' and 3' regions verified the integrity of the ORF in the end regions of each construct. The beta -subunit plasmid, pcDNA3-beta , is a 6778-bp construct with its ORF flanked by original 5'- and 3'-untranslated regions (UTR) of 27 and 405 base pairs, respectively. The 5' UTR of the beta -subunit is linked to the multiple cloning site of the pcDNA3 vector through a 16-bp sequence (AAT GGG GTA CCG AAT T), and the 3'-UTR is linked by an 11-bp sequence (TTC CTC GAA AT). The alpha -subunit, pcDNA3-alpha , is an 8784-bp construct with its ORF flanked by original 5'- and 3'-UTR of 12 and 203 base pairs, respectively. The 5'-end UTR of the alpha -subunit is linked to the multiple cloning site of the pcDNA3 vector with a 21-bp linker sequence (GGT ACC CAA TTC CTG CAG CCC), and the 3'-UTR is linked with a 24-bp linker sequence (GAT CCA CTA GTT CTA GGG GGA TCC).

DNA Sequencing-- All site mutations were verified by DNA sequencing performed by the W. M. Keck Foundation Biotechnology Resource Laboratory at Yale University. Sequence analysis was carried out on an Applied Biosystems 373A Stretch DNA Sequencer. The sequencing reactions utilized fluorescently labeled dideoxynucleotides and Taq FS DNA polymerase in a thermal cycling protocol. The submitted samples, containing 750 ng of circularized plasmid DNA and 0.4 µM oligonucleotide sequence primer, yielded approximately 600-bp sequences with >99% accuracy. The sequence primers were constructed either as sense primers complementary to a 25-bp sequence preceding the M5 transmembrane region or as antisense primers complementary to a 21-bp sequence immediately preceding the M8 transmembrane region.

Site-directed Mutagenesis-- Site-directed mutations were introduced into pcDNA3-alpha via the Quick Change site-directed mutagenesis kit (Stratagene) using the manufacture's instructions with modifications. 125 ng of pcDNA3-alpha was extended in a thermal cycler (Perkin-Elmer 2400) for 20 cycles (45 s at 95 °C, 1 min at 55 °C, 21 min at 68 °C) using 125 ng of both the mutant sense and antisense primers indicated in Table I. Following elongation, the parental strand was digested for a minimum of 1 h at 37 °C with 10 units of DpnI. Competent XL-1 Blue bacterial cells were heat shock-transformed with 1.3 µl of the DpnI-treated extension reaction, plated on LB Amp medium (0.1 mg of ampicillin/ml), and grown overnight at 37 °C. Single colonies devoid of satellites were selected and expanded by growth at 37 °C for 12-24 h in 250 ml of LB Amp medium. The plasmid was isolated using the Wizard Midi-prep kit (Promega). An aliquot of the plasmid DNA was repurified on Qiagen Spin Mini-prep columns and submitted for sequence analysis.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Mutant primers for site mutants of Glu-857
Each mutation utilized a primer pair consisting of the sense primers shown below and their identical antisense complements.

Cell Culture and Transient Transfection-- HEK293 T cells were cultured in Dulbecco's modified Eagle's medium, 10% fetal bovine serum, 2.0 mM glutamine, and 0.1 mg/ml penicillin and streptomycin at 37 °C in 95% CO2, 5% O2 atmosphere. At confluency, the cells were released by trypsin treatment, uniformly dispersed, and cultured overnight in 100-mm tissue culture dishes. At approximately 60-80% confluency, the cells were washed with serum-free Opti-MEM I supplemented with 0.9 mM CaCl2 and co-transfected with 9 µg of pcDNA3-alpha and 18 µg of pcDNA3-beta . The co-transfection procedure utilized 1.3 µl of LipofectAMINETM/µg of DNA. Following overnight incubation, 20 ml of the standard culture medium was added to the serum-free culture medium, and the cells were grown for an additional 48 h. The transiently co-transfected cells were harvested for membrane preparation at 72 h post-transfection.

Membrane Preparation-- The transiently transfected cells were washed once with PBS supplemented with 5 mM EDTA and were harvested from the plate following a brief incubation in the same medium. The cells were collected by 5 min of centrifugation at 2000 rpm and resuspended in ice-cold homogenization buffer containing 10 mM Pipes, Tris, pH 7.4, 1 mM EGTA, 0.1 mM phenylmethylsulfonyl fluoride, and 10 units/ml bovine lung aprotinin. Membranes were prepared from the cells by Dounce homogenization utilizing a 7-ml vessel and tight fitting pestle. Following a 200-stroke homogenization cycle, the membranes were diluted to a final concentration of 165 mM sucrose with 0.5 M sucrose, homogenized a final 10 strokes, and layered on a sucrose column containing 10 mM Pipes, Tris, pH 7.4, 1 mM EDTA, and 44% sucrose. Membrane fractions were resolved by 1 h of centrifugation in a Beckman SW-28 rotor centrifuged at 22,000 rpm. The membrane fraction obtained from the 44% sucrose interface was diluted 1:2 (v/v) with homogenization buffer and collected in a Beckman Ti-50.2 rotor centrifuged at 34,000 rpm for 20 min. The pellet obtained by this procedure was resuspended in 10 mM Pipes, Tris, pH 7.4, and frozen at -80 °C until assay.

Protein Quantification and Western Analysis-- Total membrane-bound protein was quantified using the Bio-Rad assay kit with gamma -globulin as standard. The quantitative Western analysis was performed on the AMBIS image acquisition and analysis system utilizing an XC-75/75CE CCD video camera module and AMBIS core (ver. 4)/ONE-Dscan software. 35-55-µg aliquots of total membrane protein were resolved by SDS-PAGE run under reducing conditions according to the method of Laemmli (50) and transferred to nitrocellulose for Western analysis. The gel was resolved by a two-step electrophoresis procedure utilizing 25 mA (constant current) for 20 min and 200 V (constant voltage) for 1 h. The SDS-PAGE-resolved protein was transferred to nitrocellulose for 3 h at 150 mA (constant current). For Western analysis the nitrocellulose membranes were blocked in 1% Carnation instant non-fat dry milk and probed with anti-beta mAb 2B-6 (1:10,000) or anti-alpha mAb 12.18 (1:5,000). The probed membranes were incubated with secondary anti-mouse horseradish peroxidase-conjugated antibody and developed according to the Amersham protocol. The expressed protein was visualized by a 15-s exposure to ECL Hyperfilm.

ATPase Analysis-- ATPase activity was measured in membrane preparations of nontransfected (control) and transiently co-transfected HEK293 T cells. Typically, 55 µg of membrane-bound protein was assayed by the method of Yoda and Hokin (51) using 1 ml of ATPase reaction buffer containing 2 mM ATP, 2 mM MgCl2, 0.1 mM ouabain, 1 mM EGTA, 50 mM Tris-HCl, pH 7.4, and 1 µg of oligomycin ± 10 mM KCl. The assay was started by the addition of ATP, incubated at 37 °C for 45 min and stopped with the addition of 1 ml of 80% ammonium molybdate, 20% perchloric acid. The expressed H,K-ATPase was differentiated from an indigenous, nonspecific phosphatase by a characteristic SCH 28080-sensitive, KCl-stimulated activity. The reported values for the K0.5 (KCl) and Ki (SCH 28080) were calculated from the global fit of n = 3 measurements from each of three separate transient co-transfection experiments. The steady-state kinetic constants were calculated from the nonlinear best fit to: K0.5 Vmax × [K+]/K0.5 + [K+] and Y = 1/(1 + [SCH 28080]/Ki) + nsb (nonspecific).

Cell Line, Antibodies, and Materials-- HEK293 T cells were a kind gift of Dr. Jamboor K. Vishwanatha. Anti-beta mAb 2B-6 was a kind gift from Dr. M. Maeda, and anti-alpha mAb 12.18 was a kind gift from Dr. A. Smolka. The sense and antisense mutant and sequencing primers were purchased from Midland Certified Reagents. LipofectAMINETM was obtained from Life Technologies, Inc.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Transient Expression of Wild Type H,K-ATPase-- The H,K-ATPase of mammalian species is organized as an alpha /beta heterodimer. The porcine alpha -subunit resolved by SDS-PAGE and probed with H,K-ATPase alpha -subunit antibody, mAb 12.18, is shown in Fig. 1, upper panel, lane 4. The alpha -subunit appears as a single band at Mr 94,000. The beta -subunit probed with H,K-ATPase beta  antibody, mAb 2B-6, is shown in lane 4 of the lower panel of Fig. 1. Because of its extensive glycosylation the beta -subunit exhibits a mobility ranging from Mr 70,000 to 80,000. Membrane preparations from HK293 T cells transiently transfected with the H,K-ATPase cDNA are shown in the remaining lanes of Fig. 1. As shown in lanes 1 and 2, either the beta - or alpha -subunit is expressed in the HK293 T cells. The cells transiently transfected with the alpha -subunit express a subunit of comparable mobility to the native H,K-ATPase. There is no evidence of smaller protein fragments suggestive of premature termination of protein synthesis or of enhanced proteolysis of the mature subunit. In contrast to the native H,K-ATPase beta -subunit, the expressed H,K-ATPase beta -subunit is resolved into four bands ranging from Mr 54,000 to 77,000. This heterogeneity is most likely because of the differential glycosylation of the Mr 34,000 core protein of the beta -subunit. As expected, because of the individual subunit expression, cells co-transfected with both alpha - and beta -cDNA also co-express both subunits. The co-expression of the alpha - and beta -subunits does not change the profile of beta -subunit maturation products from that observed with the expression of the beta -subunit alone. The membrane preparation from untransfected cells is shown in lane 5. Neither gastric H,K-ATPase alpha - or beta -subunits are expressed at detectable levels in the untransfected cells.


View larger version (45K):
[in this window]
[in a new window]
 
Fig. 1.   Subunit expression of the H,K-ATPase in HEK293 T cells. 55 µg of cell membrane protein per lane was resolved by SDS-PAGE and transferred to nitrocellulose. Top panel, lanes probed with H,K-ATPase alpha -subunit antibody, mAb 12.18. Bottom panel, lanes probed with H,K-ATPase beta -subunit antibody, mAb 2B-6. Lane 1, transfection with H,K-ATPase beta -subunit; lane 2, transfection with H,K-ATPase alpha -subunit; lane 3, co-transfection with alpha - and beta -subunits; lane 4, 0.3 µg of the native H,K-ATPase; lane 5, untransfected HEK293 T cells.

A quantitative measurement of the alpha - and beta -subunits co-expressed in three separate membrane preparations of co-transfected HK293 T cells is shown in Table II. The expressed alpha -subunit ranged from 3.8 to 7.0 µg with a mean of 5.2 ± 1.6 µg/mg of total membrane protein, whereas the beta -subunit ranged from 3.7 to 8 µg with a mean of 5.5 ± 2.3 µg of expressed protein/mg of total membrane protein. The ratio of beta - to alpha -subunit expressed in each membrane preparation ranged from 0.5 to 1.2 (w/w), although the molar ratio of the total beta -subunit population was always expressed in excess of the alpha -subunit.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Co-expression of alpha - and beta -subunits in transiently transfected HK293 T cells
HK293 T cells were co-transfected with plasmid DNA constructs containing both alpha  and beta  H,K-ATPase subunits in three separate experiments. Cell membranes were prepared 72 h post-transfection and probed for subunit expression using monoclonal antibodies to each subunit.

H,K-ATPase Activity in Transiently Transfected HK293 T Cells-- To investigate the subunit requirement for H,K-ATPase function, the alpha -subunit was transiently expressed in the presence or absence of the H,K-ATPase beta -subunit. The H,K-ATPase activity associated with alpha -subunit expression with or without the beta -subunit is summarized in Fig. 2. As indicated in the first bar of each experimental cluster, all membrane preparations of the HK293 T cells possess a nonspecific nucleotidase activity in the presence of 0.1 mM ouabain and 1 µg of oligomycin (per 55 µg of protein). This normalized activity, reported as 1, ranged from 0.8 to 1.7 µmol/mg/h in four preparations. This basal nucleotidase activity was stimulated approximately 10% by 10 mM KCl and inhibited by 55 µM SCH 28080. This activity profile was not changed with the transient transfection and expression of the alpha - or beta -subunit alone. In contrast, the co-transfection and expression of both subunits significantly increased the K+-stimulated ATPase. The mean normalized K+-stimulated activity reported in Fig. 2 is approximately 50% above that of the untransfected controls. This normalized activity represents an enhanced K+-stimulated ATPase ranging from 0.6 to 1.1 µmol/mg/h in each membrane preparation. As shown, this K+-stimulated component is inhibited by 55 µM SCH 28080.


View larger version (54K):
[in this window]
[in a new window]
 
Fig. 2.   Subunit dependence of the functional H,K-ATPase. ATPase activity in n = 3 replicates was measured in the standard ATPase buffer containing 2 mM MgCl2 (), 2 mM MgCl2 + 10 mM KCl (), or 2 mM MgCl2 + 10 mM KCl + 22 µM SCH 28080 (). The activity profiles in each preparation were normalized (norm.) to the activity measured in the presence of Mg+2 alone: activitynorm = Actmeas/ActMg2+. The specific activity in µmol/mg/h obtained in co-transfected cell membranes was: Mg+2, 1.6 ± 0.4; Mg+2 + K+, 2.3 ± 0.7; Mg+2 + K+ + SCH 28080, 1.7 ± 0.04.

The concentration dependence of the K+-stimulated activation and the SCH 28080-dependent inhibition were measured to provide a comparison of the steady-state kinetic properties of the native gastric H,K-ATPase to that expressed in the membranes of HEK293 T cells. The data from four separate co-transfected cell populations were combined in Fig. 3. The concentration dependence of the K+-stimulated activity is shown in panel A, where the activity is saturable with a K0.5 of 0.6 ± 0.1 mM KCl. Panel B shows the concentration dependence of the SCH 28080-inhibited component, where the Ki is 0.96 ± 0.3 µM. These steady-states kinetic constants resemble those of the native gastric H,K-ATPase reported in Table III.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 3.   Activation and inhibitory kinetics of the expressed H,K-ATPase. A, concentration dependence of the K+-stimulated H,K-ATPase. The data report the normalized, K+-stimulated component of H,K-ATPase activity from three separate co-transfected cell preparations. The normalized activity is reported as Vmeas/Vmax, where Vmax is the activity measured in 10 mM KCl. The line is drawn to the best fit to Y = Vmax × [K+]/K0.5 + [K+]. K0.5 = 0.6 ± 0.1 mM KCl. B, concentration dependence of SCH 28080-inhibited H,K-ATPase. The data report the SCH 28080-inhibited component of H,K-ATPase ((Mg2+ + K+- (Mg2+ + K+ + SCH 28080)) activity from three separate co-transfected cell preparations. The normalized activity is reported as the fraction of K+-stimulated activity sensitive to SCH 28080: activitynorm. = (Delta K+max - Delta SCH 28080)/Delta K+max. The line is drawn to the best fit to Y = 1/(1+ (SCH 28080)/Ki) + nsb (nonspecific). Ki = 1.0 ± 0.3 µM, nsb = 0.08.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Kinetic constants for site mutants of Glu-857
Each constant was obtained from a data set composed of three separate transfected cell membrane preparations with n = 3 replicates of each preparation. The analysis utilized the best fit to the combined data set.

Structure and Function of Glu-857-- To investigate the role of size and charge at Glu-857, site mutants were prepared to reverse the charge from negative to positive or vary the size of the uncharged side chain at this position. Each of these site mutants was co-transfected into HEK293 T cells with the H,K-ATPase beta -subunit. The alpha -subunit expressed for each site mutant is shown in Fig. 4. The Western analysis of the expressed protein confirms that all of the alpha -subunit site mutants are expressed at approximately equivalent levels. The small distortion in lane 2 is attributable to the difference in protein loading between the native H,K-ATPase (0.3 µg in lane 1) and the expressed H,K-ATPase (55 µg in lane 2) preparations.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   Expression of Glu-857 site mutants. Lanes 2-7 contain 55 µg of cell membrane protein produced by the transient co-transfection of H,K-ATPase alpha - and beta -subunits. All lanes are probed with H,K-ATPase alpha  subunit antibody, mAb 12.18. Lane 1, 0.3 µg of native H,K-ATPase; lane 2, E857R; lane 3, E857K; lane 4, E857Q; lane 5, E857A; lane 6, E857L; lane 7, untransfected control.

The steady-state activation and inhibitory constants of each site mutant were derived from pooled data taken from three separate membrane preparations of co-transfected cells. As shown in Table III, the concentration dependence of both the K+-dependent stimulation of the ATPase and the SCH 28080-dependent inhibition of the co-transfected HEK293 T (wild type) cell membranes and the native hog gastric H,K-ATPase were comparable. In addition, the specific activity of the H,K-ATPase expressed in each of the site mutants was similar to that measured for the wild type activity. Thus, the site mutations at Glu-857 do not influence the level of expression of the alpha -subunit expression nor inhibit the specific activity of the H,K-ATPase activity.

In contrast to the specific activity of the H,K-ATPase, the steady-state kinetic constants describing the K+-dependent activation and the SCH 28080-dependent inhibition of the ATPase were sensitive to various site mutants. The role of the side chain charge was evaluated either by eliminating the charge by substituting glutamine for glutamate or reversing the charge by substituting arginine or lysine for glutamate. The removal of the charge by the conservative replacement of glutamine for glutamate had little effect on the kinetic constants. In contrast, the reversal of the side chain charge from negative to positive enhanced the sensitivity to K+ but decreased the sensitivity to SCH 28080. As shown in Table III, the introduction of arginine or lysine for glutamate reduced the K0.5 (KCl) from 0.6 ± 0.1 to 0.2 ± .05 and 0.2 ± .03 mM, respectively, while increasing the Ki (SCH 28080) from 1.0 ± 0.3 to 6.5 ± 1.4 and 5.9 ± 1.5 mM, respectively. The effect of changing the side chain size was intermediate to that of reversing its charge, but the reciprocal changes noted in the charge-reversed mutants also occurred with the introduction of the bulky leucine side chain group at this position.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

This report provides evidence of the functional expression of the gastric H,K-ATPase in a mammalian HEK293 T cell line. The finding that both the alpha - and beta -subunits were required for expression of the functional H,K-ATPase confirms several biochemical investigations suggesting that the H,K-ATPase is an essential heterodimer (4-6). It is interesting that whereas the expression of the H,K-ATPase beta -subunit was essential for H,K-ATPase function, the mature alpha -subunit, free of degradation products, was expressed in the absence of the H,K-ATPase beta -subunit. This steady-state observation is somewhat unexpected because the co-translation of the alpha - and beta -subunits are necessary to stabilize the Na,K-ATPase alpha -subunit expressed in Xenopus laevis oocytes (52, 53). It is possible that the indigenous Na,K-ATPase beta -subunit present in the HEK293 T cells could stabilize the H,K-ATPase alpha -subunit, although it would then be inadequate to properly fold the functional ATPase. The data also suggest that the role of the H,K-ATPase beta -subunit in ATPase function may be fulfilled by the immature beta -subunit because several glycosylation variants of the beta -subunit were resolved by SDS-PAGE. Expression studies of the Na,K-ATPase in Xenopus oocytes have shown that the glycosylated beta -subunit is important in assembly efficiency but is not required for the functional maturation of the catalytic Na,K-ATPase alpha -subunit (54). The importance of beta -subunit glycosylation for H,K-ATPase function is uncertain because it has been shown that glycosylation inhibitors inactivate the H,K-ATPase expressed in Sf-9 cells (55, 56). The present study does not eliminate the possibility that a sufficient quantity of a complex glycosylated species is present.

The H,K-ATPase activity of cell membranes is displayed within an activity profile containing a nonspecific nucleotidase. The expressed H,K-ATPase is differentiated from the nonspecific nucleotidase by an enhanced K+-stimulated component of the ATPase that is sensitive to SCH 28080, a competitive inhibitor of the gastric H,K-ATPase. The K+-dependence of the expressed H,K-ATPase is comparable with that of the native gastric H,K-ATPase with a K0.5 (KCl) of 0.6 ± 0.1 mM and 0.5 ± 0.2 mM, respectively. Similarly, SCH 28080 inhibits the K+-stimulated ATPase of each with a Ki (SCH 28080) = 1.0 ± 0.3 µM and 0.7 ± 0.1 µM, respectively. Overall, the specific activity of the H,K-ATPase normalized for the quantity of expressed protein within the total membrane protein population is comparable with that of the native H,K-ATPase with a specific activity of 158 µmol/mg/h.

This structure-function study of Glu-857 was initiated because this residue has been identified as a K+-protected, [14C]DCCD-reactive site associated with the DCCD-dependent inhibition of the native, gastric H,K-ATPase (45). The data here show that various substitutions at this site do not inhibit the expressed H,K-ATPase and are inconsistent with the interpretation that Glu-857 is an essential hydrophobic residue. Thus, the interpretation of the previous report (57) of [14C]DCCD incorporation and inhibitory kinetics of the H,K-ATPase is that DCCD-dependent inhibition is most likely because of a secondary effect of carboxyl activation such as the cross-linkage of the carboxyl group to a nearby residue or steric hindrance of the inhibitor molecule inserted at this site. The former explanation has been proposed to account for carbodiimide inactivation of the Na,K-ATPase (57).

This investigation does show that Glu-857 is important for the concentration dependence of cation-dependent activation and inhibitor-dependent inhibition kinetics. The reversal of the side chain charge from negative to positive (Glu to Lys or Arg) altered the kinetic profile by decreasing the K0.5 for K+-dependent activation and increasing the Ki for SCH 28080-dependent inhibition of the fully active H,K-ATPase. A partial explanation consistent with previous fluorescein isothiocyanate quench studies of the native H,K-ATPase is that the residue is involved in setting the conform-ational equilibrium, Kc, between the E1 and E2 enzyme conformations. The apparent dissociation constant, Kk', derived from the K+ concentration dependence of steady-state measurements of fluorescein isothiocyanate quench, was related to Kc and the intrinsic K+ dissociation constant, Kk, through the relationship Kk' approx  Kk/Kc +1. This model predicts that the K+-dependent concentration profile will shift from 0.6 to 0.2 mM K+ in response to a 3-fold increase in the conformational equilibrium of Kc toward E2 (58). It is also likely that the structural consequence of the introduced mutations is more complex than a shift in the E1/E2 conformational equilibrium, because the reciprocal pattern of the concentrations dependence for the activating and inhibiting ligands necessarily implies that the reactivity of the catalytic intermediate, E2P, is shifted to favor K+ over SCH 28080. A further analysis of the functional consequences of these site modifications, including peptide mapping of ligand-stabilized proteolytic digests, the analysis of noncompetitive inhibitor kinetics, and the analysis of partial reactions, is beyond the scope of the present investigation.

The fourth cytoplasmic domain (C4) defined by the transmembrane spanning domains M6-M7 is a stretch of 23 amino acids beginning at Glu-835 (LAYE) and extending to Glu-857 (LVNE). Both the N- and C-terminal stretches of the domain exhibit a probability of alpha -helix formation by Chou-Fasman indices. Residues Glu-835 (LAYE), Glu-838 (KAES), and Asp-840 (DIMH) within the predicted helix of the N-terminal stretch of this domain are essential for the expression of the SCH 28080-sensitive phosphoenzyme in Sf-9 cells (59). The present investigation shows that Glu-857 in the second predicted helix of the C-terminal stretch is not essential but is an effector of the inhibitor-dependent and, to a lesser extent, the ligand-dependent kinetics of ATPase activity. The C4 domain is well conserved in the Na,K-ATPase (74%) but is nonconserved in the Ca-ATPase (1 in 23 residues). One could speculate from the kinetic signature of ATPase function and the limitation of sequence conservation to the heterodimeric isomers of the P2 ATPase family that this domain is of special significance for the relay of information between the alpha - and beta -subunits. It seems likely that this domain is one of a complex set of structural elements that contribute to the conformational equilibrium of this ATPase.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Physiology, SL39, 1430 Tulane Ave., New Orleans, LA 70112. Tel.: 504-584-2592; Fax: 504-584-2675; E-mail: erabon{at}pop.tcs.tulane.edu.

    ABBREVIATIONS

The abbreviations used are: P2, phosphoenzyme-forming ATPase family; DCCD, N,N-dicyclohexylcarbodiimide; DEAC, 4-diazomethyl-7-diethylaminocoumarin; Pipes, 1,4-piperazinediethane-sulfonic acid; SCH 28080, 2-methyl-8-(phenylmethoxy)imidazo [1,2a]pyridine-3-acetonitrile; SDS-PAGE, SDS-polyacrylamide gel electrophoresis; mAb, monoclonal antibody; bp, base pair(s); UTR, untranslated region.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Sachs, G., Chang, H. H., Rabon, E., Schackmann, R., Lewin, M., and Saccomani, G. (1976) J. Biol. Chem. 251, 7690-7698[Abstract]
  2. Lee, H. C., and Forte, J. G. (1978) Biochim. Biophys. Acta 508, 339-356[Medline] [Order article via Infotrieve]
  3. Lutsenko, S., and Kaplan, J. H. (1995) Biochemistry 34, 15607-15613[Medline] [Order article via Infotrieve]
  4. Okamoto, C. T., Karpilo, J. M., Smolka, A., and Forte, A. (1990) Biochim. Biophys. Acta 1037, 360-372[Medline] [Order article via Infotrieve]
  5. Hall, K., Perez, G., Sachs, G., and Rabon, E. (1991) Biochim. Biophys. Acta 1077, 173-179[Medline] [Order article via Infotrieve]
  6. Rabon, E. C., Bassilian, S., and Jakobsen, L. J. (1990) Biochim. Biophys. Acta 1039, 277-289[Medline] [Order article via Infotrieve]
  7. Shull, G. E., and Lingrel, J. B (1986) J. Biol. Chem. 261, 16788-16791[Abstract/Free Full Text]
  8. Bamberg, K., Mercier, F., Reuben, M. A., Kobayashi, Y., Munson, K. B., and Sachs, G. (1992) Biochim. Biophys. Acta 1131, 69-77[Medline] [Order article via Infotrieve]
  9. Maeda, M., Ishizaki, J., and Futai, M. (1988) Biochem. Biophys. Res. Commun. 157, 203-209[Medline] [Order article via Infotrieve]
  10. Newman, P. R., Greeb, J., Keeton, T. P., Reyes, A. A., and Shull, G. E. (1990) DNA Cell Biol. 9, 749-762[Medline] [Order article via Infotrieve]
  11. Jaisser, F., Horisberger, J. D., Geering, K., and Rossier, B. C. (1993) J. Cell Biol. 123, 1421-1429[Abstract]
  12. Grishin, A. V., Sverdlov, V. E., Kostina, M. B., and Modyanov, N. N. (1994) FEBS Lett. 349, 144-150[CrossRef][Medline] [Order article via Infotrieve]
  13. Crowson, M. S., and Shull, G. E. (1992) J. Biol. Chem. 267, 13740-13748[Abstract/Free Full Text]
  14. Kone, B. C., and Higham, S. C. (1998) J. Biol. Chem. 273, 2543-2552[Abstract/Free Full Text]
  15. Shull, G. E., Schwartz, A., and Lingrel, J. B. (1985) Nature 316, 691-695[Medline] [Order article via Infotrieve]
  16. MacLennan, D. H., Brandl, C. J., Korczak, B., and Green, N. M. (1985) Nature 316, 696-700[Medline] [Order article via Infotrieve]
  17. Capasso, J. M., Hoving, S. H., Tal, D. M., Goldshleger, R., and Karlish, S. J. D. (1992) J. Biol. Chem. 267, 1150-1158[Abstract/Free Full Text]
  18. Besancon, M., Shin, J. M., Mercier, F., Munson, K., Miller, M., Hersey, S., and Sachs, G. (1993) Biochemistry 32, 2345-2355[Medline] [Order article via Infotrieve]
  19. Rabon, E., Smillie, K., Seru, V., and Rabon, R. (1993) J. Biol. Chem. 268, 8012-8018[Abstract/Free Full Text]
  20. Shainskaya, A., and Karlish, S. J. D. (1994) J. Biol. Chem. 269, 10780-10789[Abstract/Free Full Text]
  21. Goldshleger, R., Tal, D. M., and Karlish, S. J. (1995) Biochemistry 34, 8668-8679[Medline] [Order article via Infotrieve]
  22. Mercier, F., Besancon, M., Hersey, S. J., and Sachs, G. (1991) FASEB J. 5, A749-A740
  23. Bayle, D., Weeks, D., and Sachs, G. (1995) J. Biol. Chem. 270, 25678-25684[Abstract/Free Full Text]
  24. Shin, J. M., Kajimura, M., Arguello, J. M., Kaplan, J. H., and Sachs, G. (1994) J. Biol. Chem. 269, 22533-22537[Abstract/Free Full Text]
  25. Bayle, D., Weeks, D., Hallen, S., Melchers, K., Bamberg, K., and Sachs, G. (1997) J. Recept. Signal Transduct. Res. 17, 29-56[Medline] [Order article via Infotrieve]
  26. Karlish, S. J. D., Goldshleger, R., and Stein, W. D. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 4566-4570[Abstract]
  27. Lutsenko, S., and Kaplan, J. H. (1994) J. Biol. Chem. 269, 4555-4564[Abstract/Free Full Text]
  28. Or, E., Goldshleger, E. D., Tal, D. M., and Karlish, S. J. (1996) Biochemistry 35, 6853-6864[CrossRef][Medline] [Order article via Infotrieve]
  29. Shainskaya, A., Nesaty, V., and Karlish, S. J. (1998) J. Biol. Chem. 273, 7311-7319[Abstract/Free Full Text]
  30. Lutsenko, S., Anderko, R., and Kaplan, J. H. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 7936-7940[Abstract]
  31. Lutsenko, S., Daoud, S., and Kaplan, J. H. (1997) J. Biol. Chem. 272, 5249-5255[Abstract/Free Full Text]
  32. Clarke, D. M., Loo, T. W., and MacLennan, D. H. (1990) J. Biol. Chem. 265, 6262-6267[Abstract/Free Full Text]
  33. Clarke, D. M., Loo, T. W., Inesi, G., and MacLennan, D. H. (1989) Nature 339, 476-478[CrossRef][Medline] [Order article via Infotrieve]
  34. Feng, J., and Lingrel, J. B (1995) Cell Mol. Biol. Res. 41, 29-37[Medline] [Order article via Infotrieve]
  35. Jewell-Motz, E. A., and Lingrel, J. B (1993) Biochemistry 32, 13523-13530[Medline] [Order article via Infotrieve]
  36. Swarts, H. G., Klaassen, C. H., de Boer, M., Fransen, J. A., and de Pont, J. J. (1996) J. Biol. Chem. 271, 29764-29772[Abstract/Free Full Text]
  37. Asano, S., Tega, Y., Konishi, K., Fujioka, M., and Takeguchi, N. (1996) J. Biol. Chem. 271, 2740-2745[Abstract/Free Full Text]
  38. Arguello, J. M., and Lingrel, J. B (1995) J. Biol. Chem. 270, 22764-22771[Abstract/Free Full Text]
  39. Kuntzweiler, T. A., Arguello, J. M., and Lingrel, J. B (1996) J. Biol. Chem. 271, 29682-29687[Abstract/Free Full Text]
  40. Arguello, J. M., and Kaplan, J. H. (1991) J. Biol. Chem. 266, 14627-14635[Abstract/Free Full Text]
  41. Gorga, F. R. (1985) Biochemistry 24, 6783-6788[Medline] [Order article via Infotrieve]
  42. Pick, U., and Racker, E. (1979) Biochemistry 18, 108-113[Medline] [Order article via Infotrieve]
  43. De Ancos, J. G., and Inesi, G. (1988) Biochemistry 27, 1793-1803[Medline] [Order article via Infotrieve]
  44. Goldshleger, R., Tal, D. M., Moorman, J., Stein, W. D., and Karlish, S. J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 6911-6915[Abstract]
  45. Rabon, E. C., Hoggatt, M., and Smillie, K. (1996) J. Biol. Chem. 271, 32137-32146[Abstract/Free Full Text]
  46. Arguello, J. M., and Kaplan, J. H. (1994) J. Biol. Chem. 269, 6892-6899[Abstract/Free Full Text]
  47. Van Huysse, J. W., Jewell, E. A., and Lingrel, J. B (1993) Biochemistry 32, 819-826[Medline] [Order article via Infotrieve]
  48. Arguello, J. M., Peluffo, R. D., Feng, J., Lingrel, J. B, and Berlin, J. R. (1996) J. Biol. Chem. 271, 24610-24616[Abstract/Free Full Text]
  49. Van Huysse, J. W., and Lingrel, J. B (1993) Cell. Mol. Biol. Res. 39, 497-507[Medline] [Order article via Infotrieve]
  50. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
  51. Yoda, A., and Hokin, L. E. (1970) Biochem. Biophys. Res. Commun. 40, 880-884[Medline] [Order article via Infotrieve]
  52. Beggah, A., Mathews, P., Beguin, P., and Geering, K. (1996) J. Biol. Chem. 271, 20895-20902[Abstract/Free Full Text]
  53. Geering, K., Beggah, A., Good, P., Girardet, S., Roy, S., Schaer, D., and Jaunin, P. (1996) J. Cell Biol. 133, 1193-1204[Abstract]
  54. Beggah, A. T., Jaunin, P., and Geering, K. (1997) J. Biol. Chem. 272, 10318-10326[Abstract/Free Full Text]
  55. Klaassen, C. H., Swarts, H. G., and de Pont, J. J. (1997) Ann. N. Y. Acad. Sci. 834, 101-103[Medline] [Order article via Infotrieve]
  56. Klaassen, C. H., Fransen, J. A., Swarts, H. G., and de Pont, J. J. (1997) Biochem. J. 321, 419-424[Medline] [Order article via Infotrieve]
  57. Pedemonte, C. H., and Kaplan, J. H. (1986) J. Biol. Chem. 261, 16660-16665[Abstract/Free Full Text]
  58. Rabon, E. C., Bassilian, S., Sachs, G., and Karlish, S. J. D. (1990) J. Biol. Chem. 265, 1594-19599[Abstract/Free Full Text]
  59. Boxenbaum, N., Daly, S. E., Javaid, Z. Z., Lane, L. K., and Blostein, R. (1998) J. Biol. Chem. 273, 23086-23092[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.